Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02659397 · ClinicalTrials.gov registry record · Phase 2
A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg
A Phase 2 study, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT02659397 is a Phase 2 study that has completed, run by Esperion Therapeutics. The registered enrollment target is 68 participants.
The verdict
NCT02659397, a Phase 2 study, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
The purpose of this research study is to measure the amount of atorvastatin and ETC-1002 in the blood, to determine how ETC-1002 affects the level of LDL-cholesterol (bad cholesterol) and other markers of health and disease in blood and urine, and to see how ETC-1002 is tolerated in the body compared to placebo when added to stable atorvastatin 80 mg background therapy in statin-treated patients.
Interventions
- DRUG Placebo
- DRUG Atorvastatin
- DRUG ETC-1002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02659397
The ClinicalTrials.gov registry entry for NCT02659397 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Esperion Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02659397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02659397 about?
NCT02659397 is a clinical study titled "A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg". The purpose of this research study is to measure the amount of atorvastatin and ETC-1002 in the blood, to determine how ETC-1002 affects the level of LDL-cholesterol (bad cholesterol) and other markers of health and disease in blood and urine, and to see how ETC-1002 is tolerated in the body compare...
What is the current status of trial NCT02659397?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2015-12. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02659397?
The interventions under investigation include: Placebo (DRUG), Atorvastatin (DRUG), ETC-1002 (DRUG).
Who is sponsoring clinical trial NCT02659397?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.